Comparison tool
Kisspeptin-10 vs Gonadorelin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Kisspeptin-10 | Gonadorelin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | KP-10, Human metastin 45-54 | GnRH, LHRH, Factrel |
| FDA approved | No | Yes |
| Clinical status | Investigational - Clinical trials ongoing
| Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
|
| What to expect | Fertility, testosterone, reproductive hormone optimization | Hormone stimulation, fertility, TRT support |
| How it works | Kisspeptin is described as acting through KISS1R/GPR54 receptors on GnRH neurons in the hypothalamus. The reported intracellular pathway includes phospholipase C activation with IP3 and DAG second messengers, followed by increased GnRH release. GnRH then drives pituitary gonadotropin output, including LH and FSH, linking kisspeptin signaling to ovarian and testicular hormone regulation. The source also notes genetic evidence: inactivating KISS1 or KISS1R mutations are associated with pubertal failure and infertility, while activating mutations are associated with precocious puberty. | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. |
| Typical dosing | 100-200 mcg subcutaneously once daily · Once daily or every other day | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump |
| Research dosing | Kisspeptin-10: 1-10 nmol/kg IV · Variable by protocol · IV (research), subcutaneous (investigational) | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump |
| Typical duration | Variable by protocol | Single dose (diagnostic) or ongoing (therapeutic) |
| Administration | IV (research), subcutaneous (investigational) | IV, subcutaneous, or pulsatile pump |
| Timing | Morning or as directed With or without food | Morning or as clinically directed With or without food |
| Evidence level | Clinical Trials | FDA Approved |
| Possible side effects |
+3 more
|
+4 more
|
| Research summary | The supplied evidence reports several human research contexts. In women with hypothalamic amenorrhea, subcutaneous kisspeptin-54 was reported to raise LH about 10-fold and FSH about 2.5-fold into the normal range, and infusion protocols were reported to restore LH pulse frequency. In an IVF setting, kisspeptin-54 was used to trigger oocyte maturation, with a live term birth reported, and the source says it has been explored as a potentially gentler trigger with possible ovarian hyperstimulation risk reduction. In hypogonadal men, kisspeptin-10 infusion reportedly increased LH roughly 5-fold and moved testosterone into the normal range. The same source cautions that these data mainly come from small academic studies and specialist infusion protocols, not large multi-center phase 3 trials, and that short-term hormone changes do not establish long-term safety. | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.